Study identifier:D798KC00001
ClinicalTrials.gov identifier:NCT06448754
EudraCT identifier:N/A
CTIS identifier:2023-509482-20
A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE-01)
Non-small Cell Lung Cancer
Phase 2
No
Volrustomig, Carboplatin, Pemetrexed
All
120
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. | Drug: Volrustomig Participants will receive volrustomig via intravenous (IV) infusion. Other Name: MEDI5752 Drug: Carboplatin Participants will receive carboplatin via IV infusion. Drug: Pemetrexed Participants will receive pemetrexed via IV infusion. |
Experimental: Arm 1 B Volrustomig dose regimen 2 + Carboplatin and Pemetrexed Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. | Drug: Volrustomig Participants will receive volrustomig via intravenous (IV) infusion. Other Name: MEDI5752 Drug: Carboplatin Participants will receive carboplatin via IV infusion. Drug: Pemetrexed Participants will receive pemetrexed via IV infusion. |